Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 4:8:563-9.
doi: 10.2147/CCID.S90270. eCollection 2015.

Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis

B Truong  1 , N Rich-Garg  2 , B D Ehst  1 , A A Deodhar  2 , J H Ku  2 , K Vakil-Gilani  2 , A Danve  2 , A Blauvelt  3
Affiliations

Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis

B Truong et al. Clin Cosmet Investig Dermatol. .

Abstract

Innovation: What is already known about the topic: psoriasis (PsO) is a common skin disease with major impact on quality of life (QoL). Patient-reported data on QoL from large number of PsO patients with and without psoriatic arthritis (PsA) are limited.

What this study adds: In a large cohort referred to a university psoriasis center, patients with PsO and concomitant PsA (~30% in this group) had greater degrees of skin and nail involvement and experienced greater negative impacts on QoL. Despite large numbers of patients with moderate-to-severe disease, use of systemic therapy by community practitioners was uncommon.

Background: PsO and PsA are common diseases that have marked adverse impacts on QoL. The disease features and patient-reported QoL data comparing PsO and PsA patients are limited.

Objective: To identify and compare demographics, clinical disease characteristics, and QoL scores in a large cohort of PsO patients with and without PsA.

Methods: All PsO patients seen in a psoriasis specialty clinic, named the Center of Excellence for Psoriasis and Psoriatic Arthritis, were enrolled in an observational cohort. Demographic, QoL, and clinical data were collected from patient-reported questionnaires and from physical examinations performed by Center of Excellence for Psoriasis and Psoriatic Arthritis dermatologists and a rheumatologists. Cross sectional descriptive data were collected and comparisons between patients with PsO alone and those with concomitant PsA are presented.

Results: A total of 568 patients were enrolled in the database. Mean age of PsO onset was 28 years and mean disease duration was 18 years. Those with family history had an earlier onset of PsO by ~7 years. Mean body surface area involvement with PsO was 14%. Mean body mass index was 30.7. Prevalence of PsA was 29.8%. PsA patients had a higher mean body surface area compared to patients with PsO alone (16.7% vs 13.4%, P<0.05), higher prevalence of psoriatic nail changes (54.4% vs 36%, P<0.0002), and worse QoL scores as assessed by the Short Form-12 (67 vs 52, P<0.00001), Psoriasis Quality of Life-12 questionnaire (62 vs 71, P<0.01), and Routine Assessment of Patient Index Data 3 (2.3 vs 4.7, P<0.01). Strikingly, 49% of patients with PsO had never received any systemic therapy.

Conclusion: These data highlight that PsO has marked negative impacts on QoL, while those patients with concomitant PsA are affected to a much greater degree. Despite large numbers of patients presenting with moderate-to-severe disease, use of systemic therapy for both PsO and PsA was uncommon.

Keywords: epidemiology; patient-reported outcomes; psoriasis; psoriatic arthritis; quality of life; treatments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Distribution of psoriatic types among 169 PsA patients. Abbreviation: PsA, psoriatic arthritis.
Figure 2
Figure 2
Disease activity and quality of life indices in patients with PsO only and those with both PsO and PsA. Abbreviations: PQOL-12, Psoriasis Quality of Life-12 questionnaire; PsA, psoriatic arthritis; PsO, psoriasis; RAPID3, Routine Assessment of Patient Index Data 3; SF-12, Short Form-12.
See this image and copyright information in PMC

References

    1. Gelfand J, Gladman D, Mease P. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(57):e1–e13. - PubMed
    1. Feldman S, Fleischer AJ, Cooper J. New topical treatments change the pattern of treatment of psoriasis: dermatologists remain the primary providers of this care. Int J Dermatol. 2000;39:41–44. - PubMed
    1. Gladman D, Schentag C, Tom B. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto psoriatic arthritis screen (ToPAS) Ann Rheum Dis. 2009;68:497–501. - PubMed
    1. Husni M, Meyer K, Cohen D. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57:481–487. - PubMed
    1. Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. - PMC - PubMed